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Our understanding of how antibodies are generated and function could help develop
effective vaccines and antibody-based therapeutics against viruses such as HIV-1, SARS
coronavirus (SARS CoV), and Hendra and Nipah viruses (henipaviruses). Although broadly
neutralizing antibodies (bnAbs) against the HIV-1 were observed in patients, elicitation
of such bnAbs remains a major challenge when compared to other viral targets. We
previously hypothesized that HIV-1 could have evolved a strategy to evade the immune
system due to absent or very weak binding of germline antibodies to the conserved
epitopes that may not be sufficient to initiate and/or maintain an effective immune
response. To further explore our hypothesis, we used the 454 sequence analysis of
a large naïve library of human IgM antibodies which had been used for selecting
antibodies against SARS CoV receptor-binding domain (RBD), and soluble G proteins (sG)
of henipaviruses. We found that the human IgM repertoires from the 454 sequencing have
diverse germline usages, recombination patterns, junction diversity, and a lower extent of
somatic mutation. In this study, we identified antibody maturation intermediates that are
related to bnAbs against the HIV-1 and other viruses as observed in normal individuals,
and compared their genetic diversity and somatic mutation level along with available
structural and functional data. Further computational analysis will provide framework for
understanding the underlying genetic and molecular determinants related to maturation
pathways of antiviral bnAbs that could be useful for applying novel approaches to the
design of effective vaccine immunogens and antibody-based therapeutics.
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INTRODUCTION
Broadly neutralizing antibodies (bnAbs) against the HIV-1 are
relatively rarely observed in patients; however, discovering HIV-
1 vaccine candidates to elicit such bnAbs remains a challenge
due to the extensive genetic sequence variability and complex
immune evasion strategies of the HIV-1 (Burton, 2002; Johnson
and Desrosiers, 2002; Haynes and Montefiori, 2006; Prabakaran
et al., 2007). Among the different factors thwarting the induction
of bnAbs, we previously found that all known HIV-1 bnAbs are
highly divergent from germline antibodies; germline antibodies
of bnAbs could not bind to the epitopes of respective mature anti-
bodies, which led to a hypothesis that HIV-1 may have evolved to
use the “holes” (absence of or weak binding to germline-lineaged
bnAbs) in the human germline B cell receptor repertoire (Xiao
et al., 2009). Consistent with our earlier hypothesis, we did not
find any specific binders against the HIV-1 envelope glycoproteins
(Envs) but only identified binders against the SARS CoV receptor-
binding domain (RBD), and soluble Hendra virus G protein (sG)
when combinatorial phage display libraries mimicking human
antibody repertoire constructing from human IgM libraries had
been used for panning experiments (Chen et al., 2012). These
findings had indicated that the major problem could be related to
a high level of somatic mutations required for bnAbs to accurately
target the conserved structures on the HIV-1 Envs.
In this article, we have used high-throughput 454 sequencing
of a large naïve library of human IgM antibodies to explore anti-
body repertoire landscape for finding germline usages, somatic
mutations, intermediates, and phylogenetic relationships between
the intermediates and corresponding antiviral-related bnAbs
including the HIV-1, SARS CoV, and henipaviruses. This study
helped to identify germline predecessors of bnAbs observed in
normal individuals, and find maturation pathways of antiviral
bnAbs. Indeed, most of the known HIV-1 bnAbs are highly diver-
gent from their closest respective germlines as well as their inter-
mediates as they undergo somatic mutations required for their
neutralization function. The results corroborate that the HIV-1
may use a strategy to eliminate strong binding of germline anti-
bodies due to the absence of closer anti-HIV antibody interme-
diates as an escape mechanism from adaptive immune responses,
and finding of closer intermediates of bnAbs from rare individuals
might help designing the effective vaccines against the HIV-1 and
other viral diseases.
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FIGURE 1 | Germline usage frequencies. The heavy (HV) and light (KV for κ
and LV for λ) chains as observed in the 454 sequencing of a human naïve IgM
library are shown in (A) and (B), respectively. The frequencies of V-genes
from heavy and light chains related to the antiviral bnAbs are shown in (C)
and (D), respectively. Data labels indicate the number of unique sequences at
the top of data points in bar plots.
Table 1 | Antiviral bnAbs against the HIV-1, SARS CoV and Henipaviruses, and their related sequence, structure, and immunogenetics data.
bnAb Viral Env PDB IGHV IGKV/IGLV Number of aa mutations HCDR3 aa sequence (length)b
target code gene gene (Identity/Similarity
in percent)a
VH VL
b12 gp120 CD4bs 2NY7 V1-3∗01 KV3-20∗01 20 (80/88) 21 (78/70) ARVGPYSWDDSPQDNYYMDV (20)
2G12 gp120 glycans 1OP5 V3-21∗01 KV1-5∗03 31 (68/85) 15 (83/91) ARKGSDRLSDNDPFDA (16)
X5 gp120 CD4i 2B4C V1-69∗01 KV3-20∗01 18 (83/94) 8 (92/95) ARDFGPDWEDGDSYDGSGRGFFDF (24)
VRC01 gp120 CD4bs 3NGB V1-2∗02 KV3-11∗01 41 (58/74) 28 (68/75) TRGKNCDYNWDFEH (14)
PG9 gp120V1/V2 3U2S V3-33∗05 LV2-14∗01 19 (81/87) 15 (85/90) VREAGGPDYRNGYNYYDFYDGYYNYHYMDV (30)
CH01 gp120V1/V2 3TCL V3-20∗01 KV3-20∗01 28 (71/86) 16 (83/90) ARGTDYTIDDAGIHYQGSGTFWYFDL (26)
PGT128 gp120 glycans 3TV3 V4-39∗07 LV2-8∗01 29 (65/81) 18 (77/87) ARFGGEVLRYTDWPKPAWVDL (21)
2F5 gp41 MPER 1TJG V2-5∗10 KV1-13∗02 14 (85/91) 14 (85/96) AHRRGPTTLFGVPIARGPVNAMDV (24)
4E10 gp41 MPER 1TZG V1-69∗10 KV3-20∗01 17 (83/95) 12 (88/93) AREGTTGWGWLGKPIGAFAH (20)
m66 gp41 MPER ND V5-51∗01 KV1-39∗01 10 (90/96) 10 (90/94) ARQNHYGSGSYFYRTAYYYAMDV (23)
m102 Henipa sG ND V1-69∗10 KV3-20∗01 6 (94/99) 9 (91/96) ARGWGREQLAPHPSQYYYYYYGMDV (25)
m396 SARS RBD 2DD8 V1-69∗05 LV3-21∗03 5 (95/95) 2 (98/99) ARDTVMGGMDV (11)
aNumber of heavy chain (VH) aa mutations were determined by IMGT/V-QUEST and confined to the V region only (excluding HCDR3 and Framework 4); Identity and
similarity between aa sequences of bnAb and its germline counterpart were based on pairwise alignment using the Needleman-Wunsch algorithm.
bHCDR3, heavy chain complementarity determining region 3, lengths follow the CDR-IMGT definition.
bnAb, broadly neutralizing antibody; CD4bs, CD4 binding site; CD4i, CD4-induced; V1/V2, variable loops V1 and V2; MPER, membrane proximal epitope region; sG,
soluble G glycoprotein; RBD, receptor binding domain; PDB, Protein Data Bank; ND, not determined; IGHV, IGKV and IGLV genes are V-REGIONS from VH, V-KAPPA
and V-LAMBDA domains respectively; aa, amino acids.
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MATERIALS AND METHODS
PCR AMPLIFICATION AND HIGH-THROUGHPUT 454 SEQUENCING
To amplify IgM antibody sequences, cDNA was prepared from
peripheral blood B cells of 10 healthy donors as received under
the Research Donor Program of Frederick National Laboratory
for Cancer Research, USA, which we previously used to construct
a naïve human Fab phage display library for selecting antibodies
against SARSCoV and henipaviruses. The complete set of primers
used in the PCR amplification of IgM-derived heavy and light
chains were described in detail elsewhere (Zhu and Dimitrov,
2009). For 454 sequencing, primer combinations used to amplify
cDNA in separate reactions included the Roche A and B adap-
tor sequences along with target amplification sequence for heavy
and light chain variable domains. The gene fragments were ampli-
fied in 20 cycles of PCR using the High Fidelity PCRMaster from
Roche. More detailed description of 454 sequencing can be found
in our recent articles (Prabakaran et al., 2011, 2012). The standard
Roche 454 GS Titanium shotgun library protocol was adapted as
found in the Roche sequencing technical bulletin.
DATABASES AND TOOLS
For quality control of antibody sequences, we trimmed the
454 sequence data and retained only sequences of length more
than 300 nucleotides (nt), covering the entire antibody variable
domains consisting of the three complementarity determining
regions (CDR) along with framework regions (FR). We used
IMGT/HighV-QUEST (Alamyar et al., 2012), a high-throughput
version for deep sequencing NGS data analysis resource for
the immunogenetic analysis. The output results from the
IMGT/HighV-QUEST analysis in CSV files were stored at
PostgreSQL database, and Structured Query Language (SQL)
was used to retrieve the data for the further analysis. Heatmap
generation and statistical calculations involving distributions of
antibody HCDR3 lengths and mutations were carried out using
SAS JMP10® statistical software (SAS Institute, Cary, NC).
COMPUTATIONAL ANALYSES OF ANTIBODY SEQUENCES
Translated heavy and light chain variable sequences from the 454
sequencing that shared the IGHV genes of selected antiviral anti-
bodies and associated immunogenetics data including the details
of germlines, HCDR3 lengths, andmutations were retrieved from
the database by using SQL. Sequence identities between the 454
sequence data and germlines were calculated based on the pair-
wise alignment using local BLAST as implemented in BioEdit
v7.0.9 (Hall, 1999). Phylogenetic analysis was carried out using
the Archaeopteryx software (Han and Zmasek, 2009).
RESULTS
GERMLINE GENE USAGES OF ANTIVIRAL bnAbs
To analyze germline origin of antiviral antibodies against the
HIV-1, SARS CoV, and henipaviruses as expressed in the human
IgM repertoire, we performed 454 sequencing of a non-immune
library which was previously constructed from peripheral blood
B cells of 10 healthy donors and used to select antibodies against
SARS CoV and henipaviruses (Prabakaran et al., 2006; Zhu et al.,
2006). A total of 113,139 sequences were obtained from which
91,528 sequences were found as unique with each had >300 nt in
length. The total number of unique amino acid (aa) sequences for
each V-gene subgroup in heavy and light chains that were found
functionally productive as determined by IMGT/HighV-QUEST
(Alamyar et al., 2012) are shown in Figures 1A,B, respectively.
The read coverage or gene frequencies observed in the study
suggested for biased germline usages and were comparable to
the previous studies (Glanville et al., 2009; Prabakaran et al.,
2012) but way far less than the theoretical diversity attainable
by antibodies attributing to several factors such as library sam-
pling, primer efficiency, and sequencing errors and limitations.
Nevertheless, we selected known bnAbs against the viral targets
including the HIV-1, SARS CoV, and henipaviruses (Table 1),
and created sequence data sets related to those bnAbs from the
454 analysis as depicted in Figures 1C,D showing the germline
usage frequencies of IGHV genes in the VH domains, IGKV,
FIGURE 2 | Distribution of heavy chain complementarity determining
region (HCDR3) lengths in (aa) (A) and VH mutations (aa) (B) of IGHV
genes related to the antiviral bnAbs.
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and IGLV genes in the Vκ and Vλ domains, respectively. We
found that while all antiviral-related germlines were expressed in
human IgM repertoire, some preferential germline usages were
noted, for example, HV1-69 gene in IGHV subgroups and KV3-
20/LV2-14 genes in IGKV/IGLV subgroups were overrepresented
(Figures 1C,D).
HCDR3 LENGTH DISTRIBUTIONS, SOMATIC VH MUTATIONS
AND UNIQUE VDJ FREQUENCIES
The role of heavy chains of antiviral antibodies in antigen recogni-
tion is found to be associated with longer HCDR3s and extensive
VH mutations (Table 1). Most of the bnAbs have longer HCDR3s
with aa lengths ranging from 20 to 30, except for 2G12, VRC01
and m396. All of the VH genes of anti-HIV-1 antibodies have a
high degree of somatic mutations when compared to non-HIV-
1 antiviral bnAbs. We analyzed HCDR3 length distributions and
VH mutations preexisting in germline-lineaged precursor antivi-
ral antibodies from the IGHV genes of IgM repertoires from
which bnAbs were generated. The box plots display the distri-
butions of HCDR3 lengths and VH mutations, Figures 2A,B,
respectively, which indicates a high level HCDR3 length diver-
sity and lesser extent of somatic mutations compared to bnAbs
(Table 1).
To assess the VDJ repertoire usage among different antivi-
ral related IGHV genes, we computed the frequencies of VDJ
recombination patterns as observed in the VH genes expressed in
human IgM repertoire involving those IGHV genes of antiviral
antibodies. The heatmap is shown in the Figure 3 depicting the
FIGURE 3 | Frequencies of VDJ recombination types as
observed in the human IgM repertoire involving IGHV genes
related to the antiviral bnAbs. The heatmap is colored according
to the total number of unique VDJ patterns existing in the
corresponding IGHV genes used in association with different IGHD
and IGHJ genes, and is shown on a blue-to-gray-to-red scale. The
white-colored space represents the missed or absent VDJ recombination
types in the repertoire.
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most (red) and least (blue) abundant VDJ types existing in the
germline-lineaged repertoire for the corresponding IGHV genes
used in association with different IGHD and IGHJ genes. The
IGHV genes V1-69 and V1-2 were frequently found to recombine
with IGHJ genes J4 and J6, and IGHD genes D3 and D6.
IDENTIFICATION OF INTERMEDIATE ANTIVIRAL bnAbs AND
GERMLINE-LINAGE ANALYSIS
The intermediate antibodies corresponding to bnAbs against the
HIV-1, SARS CoV, and henipaviruses were found by analyzing
the human IgM repertoire, and such intermediates with the clos-
est similarities to the matured antiviral bnAbs were selected for
germline-linage analysis by using phylogenetic method. IGHV
germline gene alleles of bnAbs were obtained from the IMGT
database. The mid-point phylogenetic neighbor-joining tree
showing the evolutionary relationships of different antiviral anti-
bodies with their corresponding germlines and intermediates is
given in Figure 4. We observed that some of the anti-HIV-1 anti-
bodies (2G12, CH01, and VRC01) were found at distal nodes in
the phylogenetic tree indicating high divergence from their cor-
responding germline and intermediate counterparts. In contrast,
bnAbs against SARS CoV, and henipaviruses, m396 and m102,
were found closer to their intermediates.
ANALYSIS OF INTERMEDIATES OF ANTI-HIV-1 bnAb b12 AND
MAPPING OF SOMATIC VH MUTATIONS TO THE COMPLEX
STRUCTURE
We found 169 unique IGHV sequences from the V1-3 gene fam-
ily as intermediates of bnAb b12 by using the 454 sequence
analysis of a human IgM library. Phylogenetic analysis of those
intermediates revealed two major groups, one group consisting
of germline related antibodies and the other having potential
intermediates closer to the bnAb b12. We then constructed a phy-
logenetic sub-tree selecting only the potential intermediates and
the V1-3∗01 germline along with bnAb 12. The tree was rooted
at the known germline V1-3∗01 of bnAb b12, and phylogram
showed evolutionary relationship among the different interme-
diates (Figure 5A). One of the intermediates, G3JY1, had the
maximum of 72% sequence identity (82% sequence similarity)
at aa level to the bnAb b12 (Figure 5B). However, the HCDR3
length of that intermediate was found to be 17 aa long, which is 3
aa shorter than that of b12 antibody. To find the closest HCDR3
to that of b12, we scanned 28,925 unique HCDR3 sequences
from the entire IgM 454 sequence data. We identified a HCDR3
with the same length (20 aa) and 50% sequence identity to that
of b12 (Figure 5C), which was found to be the most similar
to the HCDR3 of b12 but the IGHV gene associated with that
HCDR3 was found to be V4-b. We used the HIV-1 gp120-b12
complex structure and mapped the VH somatic mutations, which
showed the overlapping of three mutated residues of b12 (N36
fromHCDR1, Y59 fromHCDR2, andW111.1 fromHCDR3) that
contribute to the most of binding interactions with the gp120 as
previously observed (Zhou et al., 2007) (Figure 5D).
DISCUSSION
In this study, we have described the 454 sequence analysis of
a large naïve library of human IgM antibodies, and carried
FIGURE 4 | The mid-point phylogenetic neighbor-joining tree shows
the evolutionary relationships between different IGHVs of (bnAbs)
with their corresponding germlines and intermediates. The IGHV
germline gene alleles follow the IMGT nomenclature and the closest
intermediates of bnAbs as found from the human IgM repertoire were
designated with asterisks along with names of bnAbs. Some of the
anti-HIV-1 antibodies (2G12, CH01, and VRC01) were found at distal nodes
in the phylogenetic tree indicating high divergence from their corresponding
germline and intermediate counterparts.
out immunogenetic analysis to study the origin, diversity, and
maturation of selected known bnAbs against the HIV-1, SARS
CoV RBD, and henipaviruses sG proteins. We have found inter-
mediates of antiviral related bnAbs, of which most of those
against the HIV-1 were highly diverged from their mature forms
of bnAbs as compared to other viral targets, SARS CoV, and
henipaviruses.
Although antibodies are generated through various mech-
anisms involving VDJ recombination, junctional modification,
and hypermutations, the V-genes sculpt the most of the antigen-
combining sites, CDR1 and CDR2, and support frameworks for
the CDR3. We found that antiviral antibodies targeting different
Env binding regions of the HIV-1 and other viruses utilized dif-
ferent germline V-genes as the origins (Table 1). We noted that,
among antiviral-related bnAbs, the V1-69 gene usage was domi-
nated in the heavy chains while V3-20 and V2-14 genes of kappa
and lambda were used with the highest frequencies in the light
chains of human IgM repertoire (Figure 1). Accordingly, four of
the VH genes of bnAbs (4E10, X5, m102, and m396) originated
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FIGURE 5 | Phylogenetic and somatic mutation analyses of anti-HIV
bnAb b12. (A) A phylogenetic sub-tree constructed from a total of 169
unique sequences from the HV1-3 subgroup, which were obtained from the
454 sequence analysis of a human IgM library, along with the heavy chain
V1-3∗01 germline and VH sequence of b12 antibody showing the evolutionary
relationship among different intermediates. Five-letter alphanumeric codes
denote sequence labels as used in the pyrosequencing. (B) Multiple
sequence alignment shows the differences in aa sequence between
germline, intermediate, G3JY1, and b12 neutralizing antibodies. The locations
of CDRs according to IMGT numbering are shown in bold face. (C) The most
similar HCDR3 sequence to that of bnAb b12 from the IgM repertoire was
found to originate from V4-b∗01 gene and is shown in the pairwise alignment.
(D) Mapping of three of the somatically mutated residues N36, Y59, and
W111.1, as per IMGT numbering scheme, from each of the HCDRs are shown
as sticks using the complex crystal structure of HIV-1 gp120-b12 (PDB code
2NY7).
from the V1-69, and three of them paired with the kappa V3-
20 gene. One possible reason for dominance in the usage of
those germline genes could be reflecting from the relatively higher
frequencies of distributions observed in the expressed IgM reper-
toire (Figures 1A,B). The HV3 gene was used in the three of
the HIV-1 bnAbs, 2G12, PG9, and CH01. The structural data
for most of the bnAbs selected in this analysis were known and
the heavy chains of these bnAbs were dominantly used. The
increased number of VH mutations and longer HCDR3s are
characteristics for the HVI-1 bnAbs when compared to other
antiviral bnAbs (Breden et al., 2011). We analyzed the distri-
bution of HCDR3 lengths and extent of somatic VH mutations
in the human IgM repertoire to compare with that of antiviral-
related bnAbs (Figure 2). The results showed that the longer
HCDR3s and low level of somatic VH mutations as compared
to the HIV-1 bnAbs existed in the intermediates as found from
the 454 sequencing. The somatic diversity through VDJ recom-
bination involving antiviral-related V-genes in the IgM repertoire
was found high; the most abundant VDJ combination consisted
of the HV1-69 gene with certain D and J genes as depicted in gray
and red (Figure 3), which might be the reason for the preferen-
tial usage of that HV1-69 in many other viral diseases (Sui et al.,
2009).
Further, bnAbs against the SARS CoV and henipaviruses
shared the heavy chain V-gene germline, HV1-69, with two
of the HIV-1 bnAbs, 4E10, and X5. All of these four bnAbs
were less divergent from their V-germlines and intermediates,
when compared to other HIV-1 bnAbs, and formed a single
cluster at a mid-point rooted phylogenetic tree (Figure 4). The
gp41 membrane-proximal epitope region (MPER) binding site
bnAbs, 2F5, and m66, were moderately divergent from their V-
germlines and intermediates and formed distinct clusters. The
V-gene of VRC01 bnAb was the most divergent from its respec-
tive germline as well as the closest intermediate, and was placed
at a distal branch of HV1 subgroup of bnAbs. For the mid-point
rooted phylogenetic analysis, we included the closest intermedi-
ates only; however, favored maturation pathways could involve
other intermediates too. We created the germline-rooted phy-
logenetic tree as a use-case for the bnAb b12 (Figure 5A) and
analyzed the maturation pathway along different V-gene inter-
mediates from HV1-3 gene family. The closest b12 intermedi-
ate, designated as G3JY1, had three mutations each at HCDR1
and HCDR2 compared to the germline, and were found sim-
ilar though not identical to that of mature b12 (Figure 5B).
Interestingly, we also identified a HCDR3 with the same length
(20 aa) and 50% sequence identity to that of b12 (Figure 5C),
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which was found to be the most similar to the HCDR3 of b12
but the IGHV gene associated with that HCDR3 was found to be
V4-b. This might suggest for the possible maturation mechanism
of bnAbs which could be involving the VH replacement (Chen
et al., 1995). These two mutated residues (N36 from HCDR1
and Y59 from HCDR2) from the V-gene and a Trp residue from
the D-gene (W111.1 from HCDR3) contributed to the most of
binding interactions with the gp120 (Figure 5D) (Zhou et al.,
2007).
In summary, the 454 sequence analysis of a large naïve human
antibody repertoire corresponding to the selected antiviral-
related bnAbs revealed the germline V-gene usage, VDJ rear-
rangement, HCDR3 length diversity, and somatic mutations of
potential intermediate antibodies of HIV-1 and other viruses
such as SARS CoV and henipaviruses. Thus, B cell germline-
lineage analysis using the 454 sequence data from different
sources could help finding appropriate antibody intermedi-
ates, pathways, and mechanisms useful in the development
of bnAbs and vaccines against the HIV-1 and other viral
diseases.
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